WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

WuXi Biologics (02269) rose more than 7%, led by CRO concept stocks, said the US biomanufacturing bill had limited short- and medium-term impact https://finance.sina.cn/hkstock/sckxjfx/2022-09-15/detail-imqmmtha7376234.d.html?from=wap

Chinese biomed firms take ill on Biden’s decoupling order Top Chinese biomed stocks fall as US looks to reduce its reliance on foreign labs in latest tech sector to face restrictions https://asiatimes.com/2022/09/chinese-biomed-firms-take-ill-on-bidens-decoupling-order/

Daiwa Cites WUXI BIO Confidence in Retaining US Clients; Potential Impact Unclear w/o Details http://www.aastocks.com/en/stocks/news/aafn-con/now.1213248/latest-news

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1213035/company-news/HK6 M Stanley: US Unlikely to Directly Restrict US Firms' Use of CN CRO, CDMO; Mid-term Impact on WUXI BIO Limited

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1212990/company-news/HK6 Nomura: WUXI BIO Expected to Face Short-term Pressure as US Rumored to Ask Biotech Industry to Lower Dependence on CN

China Biotech Rout Shows Growing Pain From US Decoupling Drive • US efforts to boost biotech industry lead to China selloff • Traders say bilateral tensions may see more sectors targeted https://www.bloomberg.com/news/articles/2022-09-13/china-biotech-rout-shows-growing-pain-from-us-decoupling-drive?srnd=premium-europe The latest US effort to reduce reliance on China is striking hard at the Asian nation’s biotech stocks, as investors price in more indications of decoupling between the world’s two biggest economies.    ... The key question facing traders now is which sector will be the next to be targeted by American officials.  The US “could move the sanctions down along the supply chain in the areas that’s already sanctioned, such as semiconductor and biotech segments,” said Dai Ming, Shanghai-based fund manager at Huichen Asset Management. It may also target areas that may threaten US position, such as new energy and AI-related industries, he said.  ...

Moonshot Weighs On Wuxi While Nio Fans Rejoice In ET5 Launch https://www.forbes.com/sites/brendanahern/2022/09/13/moonshot-weighs-on-wuxi-while-nio-fans-rejoice-in-et5-launch/ ... Hong Kong and Chinese biotech stocks were hit hard after President Biden’s Cancer Research "Moonshot" initiative was launched, presenting the potential for onshoring contract research that is currently done by Chinese firms. The initiative aims to find a cure for cancer by growing the US biotech industry, which investors took as a negative for Chinese biotech and healthcare companies. Wuxi Biologics (2269 HK) was Hong Kong’s most heavily traded stock by value today, falling -19.94% while WuXiAppTec (2359 HK) fell -16.82% as investors shot first before asking questions. Big companies like Wuxi already have significant operations in the United States so the reaction feels overdone. ...

Morgen bestimmt positiv

Was Denkt ihr! Jetzt Nachkaufen oder noch 1-2Tage warten?

Heute zerreißt es sie ja förmlich. Ich hoffe es ist nicht von Dauer

After the Hang Seng Index fell 63 points, it rose 109 points and WuXi decimated 20% https://m.hkej.com/landing/mobarticle2?id=3245272 ... Foreign sources quoted news that US President Biden is about to sign a new executive order to expand US bio-manufacturing to reduce dependence on China. The pharmaceutical outsourcing service industry (CXO) was sold out across the board this morning. ....

https://finance.sina.cn/hkstock/sckxjfx/2022-09-09/detail-imqqsmrn8424147.d.html?from=wap

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey https://www.prnewswire.co.uk/news-releases/wuxi-biologics-announces-gmp-release-of-its-first-north-american-biomanufacturing-facility-in-cranbury-new-jersey-819520512.html

http://www.takungpao.com/finance/236135/2022/0823/756604.html Share Screening

Lyon: Maintain "Outperform" rating on WuXi Biologics (02269), target price raised to HK$84 https://finance.sina.cn/hkstock/ggpj/2022-08-22/detail-imizmscv7204955.d.html?from=wap

"Research Report" Goldman Sachs downgrades WuXi Biologics (02269.HK) earnings forecast to reflect slightly lower gross profit rating "Buy http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1206110/3